Silicon quantum dot optical probes
Systems comprising a nanocrystal and a luminescent chromophore are disclosed herein. The luminescent chromophore can emit energy having a first wavelength. The luminescent chromophore is configured to transfer the emitted energy having a first wavelength to the nanocrystal. The luminescent chromophore can be linked to the nanocrystal via a covalent bond. Absorption of the energy having first wavelength by the nanocrystal can activate the nanocrystal and result in an increase in quantum yield. In some embodiments, the nanocrystal can include silicon, germanium, carbon, or combinations thereof. In some examples, the luminescent chromophore can be pyrene. The luminescent chromophore and the silicon containing nanocrystal can be in a ratio of about 1:1 to 100:1 in the nanocrystal system. Methods of making and using the system are also disclosed.
1. A photoactive particle comprising:
a pyrene luminescent chromophore covalently bonded to a silicon nanocrystal, wherein the photoactive particle exhibits an absorption spectrum including a first wavelength and a photoluminescence emission spectrum for excitation at the first wavelength, and wherein the photoactive particle exhibits an external photoluminescence quantum yield of at least 10%, wherein the external photoluminescence quantum yield corresponds to a number of photoluminescent photons emitted by the photoactive particle per incident photon having a wavelength in the absorption spectrum.
2. The photoactive particle of claim 1 , wherein from 1 to 100 pyrene luminescent chromophores are covalently bonded to the silicon nanocrystal.
3. The photoactive particle of claim 1 , wherein the pyrene luminescent chromophore is biocompatible.
4. The photoactive particle of claim 1 , wherein the first wavelength corresponds to electromagnetic radiation having the first wavelength.
5. The photoactive particle of claim 1 , wherein the pyrene luminescent chromophore comprises pyrene or a pyrene derivative.
6. The photoactive particle of claim 1 , wherein the silicon nanocrystal is biocompatible.
7. The photoactive particle of claim 1 , wherein the silicon nanocrystal is linked to the pyrene luminescent chromophore by a C1-C50 alkyl, alkenyl, or alkynyl linker.
8. The photoactive particle of claim 1 , wherein the silicon nanocrystal is linked to the pyrene luminescent chromophore by a C1-C8 alkyl group.
9. The photoactive particle of claim 1 , wherein the silicon nanocrystal is linked to the pyrene luminescent chromophore by a C8-C20 alkyl group.
10. The photoactive particle of claim 1 , wherein the silicon nanocrystal is from 1 to 10 nm in diameter.
11. The photoactive particle of claim 1 , wherein the photoactive particle exhibits a molar absorption coefficient at the first wavelength of from about 4.4×10 4 M −1 cm −1 to about 15.9×10 5 M −1 cm −1 .
12. The photoactive particle of claim 1 , wherein the external photoluminescence quantum yield is at least double an external photoluminescence quantum yield of the silicon nanocrystal only.
13. The photoactive particle of claim 1 , wherein the first wavelength is from 345 nm to 378 nm.
14. The photoactive particle of claim 1 , wherein the photoluminescence emission spectrum includes wavelengths of from 400 to 970 nm.
15. The photoactive particle of claim 1 , wherein the photoactive particle exhibits a brightness intensity of from 4.4×10 3 M −1 cm −1 to 6.36×10 5 M −1 cm −1 .
16. The photoactive particle of claim 1 , wherein the photoactive particle exhibits an absorbance 300% more or greater than the silicon nanocrystal only.
17. The photoactive particle of claim 1 , wherein the photoactive particle exhibits a luminescent excited state lifetime of from 50 μs to 190 μs.
18. The photoactive particle of claim 1 , wherein a brightness intensity of the photoactive particle is 300% more or greater than the silicon nanocrystal only.
19. The photoactive particle of claim 1 , a cell recognition moiety bonded to the silicon nanocrystal, wherein the cell recognition moiety is selected from the group consisting of a receptor, ligand, polynucleotide, peptide, polynucleotide binding agent, antigen, antibody, or combinations thereof.
20. The system A mixture comprising the photoactive particle of claim 1 and a carbon allotrope.
21. A composition comprising, a plurality of the photoactive particles according to claim 1 .
22. A pharmaceutical composition, comprising:
the photoactive particle according to claim 1 , and
a pharmaceutically acceptable excipient.
23. A method of making the photoactive particle according to claim 1 , comprising
providing a silicon nanocrystal,
providing a solution of the pyrene luminescent chromophore configured to covalently link to the silicon nanocrystal,
dispersing the silicon nanocrystal in the solution of the pyrene luminescent chromophore to form a dispersion of the silicon nanocrystal in the solution of the pyrene luminescent chromophore, and
heating the dispersion of the silicon nanocrystal in the solution of the pyrene luminescent chromophore.
24. The method of claim 23 , further comprising dispersing the silicon nanocrystal in a solution of a linking agent, wherein the linking agent comprises a moiety reactive with the silicon nanocrystal.
25. The method of claim 24 , wherein the moiety of the linking agent reactive with the silicon nanocrystal includes an alkenyl group.
26. The method of claim 24 , wherein the linking agent is a C1-C50 alkyl, alkenyl, or alkynyl.
27. The method of claim 24 , wherein linking agent is a C1-C8 alkyl group.
28. The method of claim 24 , wherein linking agent is a C8-C20 alkyl group.
29. The method of claim 24 , wherein the pyrene luminescent chromophore and the linking agent are in a ratio 1:1 to 1:50.
30. A method of increasing photoluminescence quantum yield of a silicon nanocrystal, the method comprising the steps of:
providing a silicon nanocrystal, and
treating the silicon nanocrystal with a molar excess of a pyrene luminescent chromophore configured to covalently bind to the silicon nanocrystal, thereby forming the photoactive particle of claim 1 .
31. The method of claim 30 , further comprising exposing the photoactive particle to electromagnetic radiation having the first wavelength.
32. The method of claim 30 , wherein the silicon nanocrystal is from 1 to 10 nm in diameter.
33. The method of claim 30 , wherein the photoactive particle exhibits a greater intensity of brightness than the silicon nanocrystal before treating.
34. The method of claim 30 , wherein the photoactive particle exhibits a brightness increase of about 300% more than the silicon nanocrystal before treating.
35. The method of claim 30 , wherein the photoactive particle exhibits a photoluminescence quantum yield at least double that of the silicon nanocrystal before treating.